for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sumitomo Chemical Co Ltd

4005.T

Latest Trade

515.00JPY

Change

12.00(+2.39%)

Volume

12,052,300

Today's Range

513.00

 - 

518.00

52 Week Range

443.00

 - 

593.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
503.00
Open
515.00
Volume
12,052,300
3M AVG Volume
152.69
Today's High
518.00
Today's Low
513.00
52 Week High
593.00
52 Week Low
443.00
Shares Out (MIL)
1,635.01
Market Cap (MIL)
832,689.40
Forward P/E
11.33
Dividend (Yield %)
4.37

Next Event

Q3 2020 Sumitomo Chemical Co Ltd Earnings Release

Latest Developments

More

Meridian Energy Says Rio Tinto Intends To Initiate A Strategic Review Of NZAS

Nufarm Announces Sale Of Nufarm South America To Sumitomo For $1,188 Million

Nufarm Announces Placement Of $97.5 Mln Preference Securities To Sumitomo Chemical Co

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sumitomo Chemical Co Ltd

SUMITOMO CHEMICAL COMPANY, LIMITED is a Japan-based company engaged in the comprehensive chemical business. The Company operates in five business segments. Petrochemicals segment provides petrochemicals, inorganic chemicals, and synthetic resin processed products. Energy & Functional Materials segment provides alumina products, additives, and battery components. Information Electronics segment provides optical products, color filters, and semiconductor process materials. Health & Agriculture-Related segment provides agricultural chemicals, fertilizers, pesticides, tropical infectious disease control materials. Pharmaceuticals segment provides prescription drugs, radiodiagnostics, and other products. The Company is also involved in the supply of electricity and steam, the design and construction supervision of chemical industry facilities, the transportation and warehousing business, as well as the physical property analysis and environmental analysis business.

Industry

Chemical Manufacturing

Contact Info

Tokyo Sumitomo Twin Bldg. East Kan

2-27-1, Shinkawa

+81.3.55435500

https://www.sumitomo-chem.co.jp/

Executive Leadership

Masakazu Tokura

Chairman of the Board, Representative Director

Keiichi Iwata

President, Executive President, Representative Director

Rei Nishimoto

Executive Vice President, Chairman of Subsidiary, Representative Director

Hiroshi Ueda

Executive Vice President, Director

Hiroshi Niinuma

Senior Managing Executive Officer, Director

Key Stats

2.58 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

2.0K

2018

2.2K

2019

2.3K

2020(E)

2.3K
EPS (JPY)

2017

52.310

2018

81.810

2019

72.170

2020(E)

44.404
Price To Earnings (TTM)
9.55
Price To Sales (TTM)
0.36
Price To Book (MRQ)
0.85
Price To Cash Flow (TTM)
3.36
Total Debt To Equity (MRQ)
99.38
LT Debt To Equity (MRQ)
64.26
Return on Investment (TTM)
6.61
Return on Equity (TTM)
3.74

Latest News

Latest News

UPDATE 1-Australia's Nufarm cuts 2019 outlook, turns to Japan's Sumitomo for cash

Australian crop protection company Nufarm Ltd on Thursday cut its fiscal 2019 earnings guidance and said it would raise about A$97.5 million ($66.8 million) through a share placement with Japan's Sumitomo Chemical Co Ltd .

BRIEF-Sumitomo Chemical Halts Production Of Material Used In LED At JV With Samsung Electronics - Nikkei

* SUMITOMO CHEMICAL HAS HALTED PRODUCTION OF A MATERIAL USED IN LED AT A JV WITH SAMSUNG ELECTRONICS - NIKKEI Source text: Further company coverage:

BRIEF-Kayac to buy system for 70 mln yen

* Says it will buy a system for 70 million yen from SuMiKa Co.,Ltd., effective Sept. 19

BRIEF-Sumitomo Chemical buys Kyowa Hakko's agrochemical segment - Nikkei

* Sumitomo Chemical Co Ltd to buy Kyowa Hakko Kirin's agrochemical segment in deal valued at 6 billion yen to 7 billion yen

BRIEF- Sumitomo Chemical unit Sumitomo Dainippon Pharma announces unblinding of phase 3 study of Napabucasin

* Says its unit Sumitomo Dainippon Pharma Co Ltd announced today that the company decided to unblind the BRIGHTER study, a phase 3 global study in patients with gastric and gastro-esophageal junction (GEJ) cancer of napabucasin, an investigational cancer stemness inhibitor...

BRIEF-Sumitomo Chemical to buy out its JV with Trinseo - Nikkei

* Sumitomo Chemical to buy out its joint venture with America's Trinseo for tens of millions of dollars - Nikkei Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up